Butea monosperma for Health & Longevity

Evidence Review created on 10/14/2026 using AI4L + evidence-mcp / Gemini 3.1

Also known as: Butea frondosa, Erythrina monosperma, Palash, Palasha, Flame of the Forest, Bastard Teak, Dhak, Tesu, Kinshuka, Parrot Tree, Butea Gum, Bengal Kino, Kamarkas

Motivation

Butea monosperma (commonly known as palash or flame of the forest) is a deciduous tree native to South and Southeast Asia whose bark, flowers, leaves, seeds, and resinous gum have distinct chemical profiles. In health and longevity research, the plant draws interest for its isolated stem bark and flower compounds, which have been investigated for influencing bone-forming cell signaling and cellular inflammatory pathways.

Practitioners of traditional Indian medicine have administered different parts of the tree for centuries to address bone fractures, digestive parasites, and urinary tract disorders. More recently, pharmacological laboratories have isolated specific ring-structured plant compounds from the stem bark and bright orange-red flowers to investigate how they interact with bone remodeling, blood sugar regulation, and cellular energy expenditure, while toxicology teams have examined how the seeds differ from the bark and flowers in organ safety.

This review examines the scientific evidence for Butea monosperma across human clinical studies and laboratory models, separating the candidate benefits, organ toxicities, dosing regimens, and quality standards of its individual plant parts for health and longevity.

Benefits - Risks - Protocol - Conclusion

This section curates foundational narrative reviews and primary mechanistic studies that examine the phytochemistry, bone-remodeling activity, and cellular signaling pathways of Butea monosperma and its principal bioactive compounds.

No coverage of Butea monosperma was found on the prioritized platforms of Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io because the botanical remains a regional Ayurvedic remedy investigated primarily in preclinical ethnopharmacology rather than Western clinical longevity trials.

Grokipedia

Butea monosperma

Provides a structured overview of Butea monosperma taxonomy, botanical morphology, ecological role, traditional ethnomedicinal uses across plant parts, and preclinical research on its bioactive flavonoids and seed compounds.

Examine

Butea monosperma benefits, dosage, and side effects

Summarizes preclinical evidence for Butea monosperma stem bark isoflavones (plant polyphenols) such as cajanin, cladrin, isoformononetin, and medicarpin, highlighting their non-estrogenic bone-forming activity in rodents and the absence of human trials.

ConsumerLab

No dedicated article or product review for Butea monosperma was found on ConsumerLab.

Systematic Reviews

This section lists systematic reviews that include Butea monosperma preparations; while one covers urinary stone efficacy and one evaluates cellular toxicity of plant-synthesized nanoparticles, standalone systematic reviews or meta-analyses of its primary longevity-related benefits and systemic human clinical risks remain unrepresented in the literature.

Mechanism of Action

Butea monosperma acts via tissue-specific pathways. Stem bark isoflavones (cajanin, isoformononetin, cladrin) and medicarpin stimulate osteoblast (bone-building cell) differentiation. Views on estrogen binding differ: crude bark extracts and docking models suggest phytoestrogenic (estrogen-like) activity (Pandey et al., 2010; Sindhu & Sripathi, 2026), whereas standardized fractions patented by the Central Drug Research Institute (an institutional conflict of interest), cajanin, and cladrin drive bone formation non-estrogenically via MAPK (mitogen-activated protein kinase, a growth cascade), Notch (a cell-fate pathway), Wnt/β-catenin, and AMPK/mTOR (AMP-activated protein kinase and mechanistic target of rapamycin, energy and clearance regulators) (Bhargavan et al., 2009; Rai et al., 2022).

Flower chalcones (aromatic ketone polyphenols) and flavanones (butein, isobutrin, butrin) inhibit IKK (inhibitor of nuclear factor-kappaB kinase, an inflammatory enzyme) to suppress NF-κB, IL-6 (interleukin-6, an inflammatory cytokine), and MMP (matrix metalloproteinase, cartilage-degrading enzymes), while activating SIRT1 (sirtuin 1, a longevity deacetylase) and UCP1 (uncoupling protein 1, a thermogenic protein) (Rasheed et al., 2010; Jang et al., 2021). Seed palasonin inhibits protein phosphatases (phosphate-removing enzymes) (Ren & Kinghorn, 2021). In rats, medicarpin shows rapid absorption (15-minute peak), 17% bioavailability, 82% protein binding, a 5-hour half-life, liver and marrow uptake, UGT (uridine 5’-diphospho-glucuronosyltransferase, conjugation enzymes) metabolism, and CYP (cytochrome P450, drug-metabolizing enzymes) inhibition (Taneja et al., 2015; Taneja et al., 2020; Wang et al., 2019; Friedman et al., 1985).

Historical Context & Evolution

Documented in Sanskrit as Palasha since the Vedic period and featured in the classical Ayurvedic texts Charaka Samhita and Sushruta Samhita, Butea monosperma served as sacred ritual wood and a multi-part medicine (Prasad et al., 2006). Traditional practitioners used the seeds (Palasha Bija) against intestinal roundworms, the astringent ruby-red gum (Bengal kino or Kamarkas) for diarrhea, the flowers for liver and inflammatory ailments, and the stem bark or alkaline ash (Palasha Kshara) for bone fractures and urinary stones (Hiremath et al., 2024).

Research in the 1960s and 1970s isolated seed palasonin, confirming roundworm paralysis (Raj & Kurup, 1968) and anti-implantation antifertility effects in female rats (Razdan et al., 1969; Garg et al., 1970). In 1986, Wagner and colleagues identified flower-derived isobutrin and butrin as liver-protective agents (Wagner et al., 1986). Interest shifted to skeletal optimization in the late 2000s when the Central Drug Research Institute (which patented standardized bark fractions for bone disorders) reported that bark methoxyisoflavones and medicarpin stimulated bone formation in ovariectomized (surgically ovary-removed) rats (Maurya et al., 2009; Pandey et al., 2010). Later work identified sirtuin-activating and thermogenic effects of flower chalcones (Jang et al., 2021), while chronic rat toxicology demonstrated nephrotoxicity (kidney toxicity) from crude seed powder (Donga et al., 2011).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: human clinical trials of Butea monosperma are limited to small multi-herb combination studies, while standalone efficacy data come from rodent models and in-vitro cellular assays.

Medium 🟩 🟩

No benefit reaches Medium: the only controlled human trials tested Butea monosperma co-administered with other botanicals rather than as a standalone intervention, and all monotherapy data come from preclinical animal and cell studies.

Low 🟩

Urinary Stone Symptom Relief and Clearance ⭕️ Not Central to Health & Longevity

This outcome concerns acute urinary stone care rather than longevity. In an open-label randomized trial of 39 urolithiasis patients (Kumari & Tukaram, 2022), oral Butea monosperma alkali (Palasha Kshara) reduced renal pain, urinary frequency, and stone burden. Evidence is indirect because Butea monosperma was co-administered with Ashmarihara Kwatha decoction.

Magnitude: 9.73 percentage points higher kidney stone expulsion than placebo over 2 months (29.73% of 37 stones vs. 20.0% of 35 stones; not statistically compared between groups), 14.21 percentage points higher stone-size reduction (51.35% vs. 37.14%), 75% (3/4) vs. 0% (0/5) ureteric stone expulsion, and 37.5 percentage points greater urine microbial load reduction (37.5% vs. 0%), alongside greater reductions in renal pain (between-group p < 0.00001) and urinary frequency (p = 0.0064; 95% CI [confidence interval, the range of plausible true effect values] not reported).

Intestinal Parasite Clearance in Giardiasis ⭕️ Not Central to Health & Longevity

This outcome bears on acute infectious gastroenteritis treatment rather than longevity. In a double-blind placebo-controlled trial of 50 patients with giardiasis (an intestinal parasite infection) (Agarwal et al., 1997), Pippali Rasayana cleared Giardia lamblia parasites and cysts. Evidence is indirect because Butea monosperma was combined with Piper longum.

Magnitude: 72 percentage points higher stool parasite clearance than placebo after 15 days (92% [23/25] in the intervention group vs. 20% [5/25] in the placebo group; 95% CI not reported).

Speculative 🟨

Bone Density Preservation and Osteogenesis

Stem bark methoxyisoflavones (cajanin, isoformononetin, cladrin) and medicarpin stimulate osteoblast differentiation via Wnt and Notch signaling (Pandey et al., 2010; Dixit et al., 2015). Evidence is restricted to rodent ovariectomy models without human trials.

Glycemic and Lipid Regulation ⚠️ Conflicted

Ethanolic bark extracts lowered glucose and lipids in diabetic rats (Divya & Mini, 2014), whereas aqueous extracts showed insignificant glycemic effects (Ahmed et al., 2012). No human trials exist. Efficacy depends on alcoholic extraction.

Cartilage and Skin Anti-Inflammatory Protection

Flower isobutrin, butrin, and butein inhibit inflammatory enzymes and cytokines while activating autophagy (cellular self-cleaning) in human cartilage and skin cells (Ansari et al., 2017; Krolikiewicz-Renimel et al., 2013). Evidence is cellular only.

Thermogenesis and Weight Gain Attenuation

Butein-enriched flower fractions induce fat-cell UCP1 expression, increasing oxygen consumption and attenuating weight gain in obese mice (Jang et al., 2021; Chang et al., 2024). Evidence relies solely on rodent and cell models.

Hepatoprotection and Nephroprotection Against Toxins

Bark, leaf, and flower extracts containing isobutrin and butrin reduce toxin-induced liver and kidney injury in rats (Kaur et al., 2017; Sonkar et al., 2014; Wagner et al., 1986). Evidence is animal-only.

Neuroprotection and Stress Resilience

Leaf extracts and flower butrin reduce drug-induced memory loss, stress anxiety, and neuroinflammation in rodents (Soman et al., 2004; Malik et al., 2013; Prabhu et al., 2025). Evidence is limited to animal studies.

Benefit-Modifying Factors

  • Genetic polymorphisms and gut metabotype: Because rat studies show isoformononetin and medicarpin undergo liver demethylation, glucuronidation, and equol conversion (Raju et al., 2019; Wang et al., 2019), CYP1A2 (demethylation enzyme) and UGT1A1 (conjugation enzyme) variants plus gut equol production may theoretically modify active metabolite levels.
  • Baseline biomarker levels: Preclinical responses are largest when baseline BMD is low or fasting glucose, triglycerides, osteocalcin (a bone-turnover protein marker), and CTX-I (C-terminal telopeptide of type I collagen, a bone-resorption marker) are elevated (Pandey et al., 2010; Divya & Mini, 2014).
  • Sex-based differences: Estrogen-deficient states in postmenopausal females amplify the bone-conserving effects of stem bark methoxyisoflavones and medicarpin, although supplementation in ovary-intact female rats during growth also increased peak bone mass accrual (Pandey et al., 2010; Srivastava et al., 2013).
  • Pre-existing health conditions: Osteopenia (mildly reduced bone density), insulin resistance, and dyslipidemia (abnormal blood lipid levels) increase potential responsiveness to standardized alcoholic bark or flower extracts, whereas severe pancreatic beta-cell destruction blunts glycemic response to aqueous extracts (Ahmed et al., 2012).
  • Age-related considerations: Older adults with age-related declines in osteoblast Wnt signaling and cellular autophagy represent the primary target profile for stem bark and flower bioactives, though age-related reductions in digestive blood flow may further limit oral flavonoid absorption (Kong et al., 2026).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human clinical trials from independent research groups have documented or quantified adverse events from Butea monosperma administration, and all known toxicities derive from rodent and in-vitro studies.

Medium 🟥 🟥

No risk reaches Medium: available controlled human trials did not report adverse-event rates, leaving only animal toxicology and cellular assays to characterize potential harms.

Low 🟥

Speculative 🟨

Nephrotoxicity, Hypoalbuminemia, Hyperlipidemia, and Anemia from Seed Preparations ⚠️ Conflicted

Chronic rat seed-powder dosing caused renal hemorrhage, hypoalbuminemia (low blood albumin), elevated triglycerides, and anemia (Donga et al., 2011), whereas flower extract showed no toxicity (Khan et al., 2017). Toxicity is seed-specific.

Male Spermatogenic Suppression and Testicular Impairment

Oral flower extract or seed powder in male rats disrupted spermatogenesis (sperm production), reduced motility, and lowered fertility by 40%, reversing after withdrawal (Parween et al., 2021; Donga et al., 2011). Evidence is animal-only.

Female Implantation Failure and Uterotrophic Modulation ⚠️ Conflicted

Seed and crude bark extracts suppressed embryo implantation (Garg et al., 1970; Donga et al., 2011), whereas standardized bark fractions lacked uterogenicity (uterine stimulation) (Pandey et al., 2010). Evidence is animal-only and tissue-specific.

Gastrointestinal Mucosal Disruption and Splenic Hypocellularity

Chronic rat seed powder damaged intestinal lining cells and reduced spleen cell density (Donga et al., 2011), attributed to palasonin and seed lectins (sugar-binding proteins) (Ayouba et al., 1992). Evidence is rodent-only.

Risk-Modifying Factors

  • Genetic polymorphisms: Because medicarpin and related isoflavones undergo hepatic CYP oxidation and UGT glucuronidation in rats (Wang et al., 2019; Friedman et al., 1985), slow-metabolizer UGT1A1 or CYP variants may theoretically reduce clearance and increase systemic tissue accumulation.
  • Baseline biomarker levels: Low baseline eGFR (estimated glomerular filtration rate, a blood measure of kidney filtration), low serum albumin, high triglycerides, or low hemoglobin increase vulnerability to seed-associated nephrotoxicity, hypoalbuminemia, dyslipidemia, and anemia (Donga et al., 2011).
  • Sex-based differences: Males face reversible sperm suppression from flower or seed extracts (Parween et al., 2021), while females face implantation loss and uterotrophic (uterine growth) shifts from unfractionated bark or seeds (Garg et al., 1970; Pandey et al., 2010).
  • Pre-existing health conditions: Chronic kidney disease, hypoalbuminemia, hypertriglyceridemia (elevated blood triglycerides), anemia, inflammatory bowel disease, or estrogen-receptor-positive malignancies heighten organ and endocrine risks from crude extracts (Donga et al., 2011; Sindhu & Sripathi, 2026).
  • Age-related considerations: Older adults with declining renal reserve and higher polypharmacy exposure face elevated risks of nephrotoxicity from seed adulteration and CYP-mediated drug interactions (Friedman et al., 1985).

Key Interactions & Contraindications

  • Antidiabetic prescription medications (metformin, glimepiride, insulin): Caution (theoretical); ethanolic bark and leaf extracts lower blood glucose and increase plasma insulin in diabetic rats (Divya & Mini, 2014), creating an additive hypoglycemia risk. Monitor fasting glucose and titrate medication doses if combined.
  • Hepatic CYP substrates (warfarin, phenytoin, theophylline): Monitor (theoretical); medicarpin inhibits rat hepatic CYP aryl hydrocarbon hydroxylase and ethoxycoumarin deethylase (liver drug-metabolizing enzymes) (Friedman et al., 1985). Co-administration may elevate substrate levels; stagger dosing by 3–4 hours and monitor narrow-index drugs.
  • Estrogen-receptor modulators and hormones (raloxifene, tamoxifen, estradiol): Monitor (theoretical); co-administered cladrin and raloxifene were quantified in rats without testing human interaction safety (Chauhan et al., 2024), and crude bark shows mild estrogenicity (Pandey et al., 2010). Use only standardized non-estrogenic bark fractions.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen, aspirin) and acetaminophen: Avoid with seeds / Caution with bark or flowers (theoretical); seed powder causes rat renal bleeding and gut injury (Donga et al., 2011), compounding NSAID renal and gut risk. Monitor kidney labs.
  • Glucose-lowering supplements (berberine, alpha-lipoic acid, Gymnema sylvestre): Monitor (theoretical); combining antihyperglycemic supplements with alcoholic Butea monosperma bark or leaf extracts (Farooq et al., 2020) may produce additive blood glucose reductions. Track fasting and postprandial glucose when stacking.
  • Phytoestrogenic supplements (soy isoflavones, red clover, Pueraria mirifica): Caution (theoretical); isoformononetin converts to daidzein and equol (Raju et al., 2019), risking additive estrogenic stimulation when combined with crude bark extracts (Pandey et al., 2010). Avoid concurrent high-dose isoflavone stacking.
  • Prolonged fasting and ketogenic diets: Monitor (theoretical); pairing prolonged fasting with alcoholic bark or flower extracts may amplify glucose lowering (Divya & Mini, 2014) and UCP1-mediated thermogenesis (Jang et al., 2021). Administer extracts with meals rather than during multi-day fasts.

Populations who should avoid Butea monosperma:

  • Pregnant and lactating women: Seed and flower extracts suppress embryo implantation and alter uterine and fetal development in rodent models (Garg et al., 1970; Donga et al., 2011).
  • Men and women actively trying to conceive: Oral methanolic flower extract (500 mg/kg/day for 180 days) reduced male rat fertility by 40% (Parween et al., 2021), and seed extracts block female implantation (Razdan et al., 1969).
  • Individuals with renal impairment, hypoalbuminemia, or anemia: Chronic seed administration in rats caused renal fatty changes, glomerular congestion and tubular hemorrhage (kidney filter congestion and tubule bleeding), hypoalbuminemia, and reduced hemoglobin and hematocrit (Donga et al., 2011).
  • Individuals with hormone-sensitive malignancies: Crude stem bark extracts demonstrated uterotrophic activity in ovariectomized rats (Pandey et al., 2010), and flower flavonoids exhibit computational estrogen-receptor binding (Sindhu & Sripathi, 2026).

Risk Mitigation Strategies

Doses, timings, and monitoring intervals below follow common practice unless cited.

  • Strict exclusion of seed preparations: Eliminating Butea monosperma seed powders and oils from longevity regimens prevents palasonin- and lectin-induced renal hemorrhage, hypoalbuminemia, hypertriglyceridemia, small-intestinal mucosal injury, and anemia (Donga et al., 2011; Raj & Kurup, 1968).
  • Use of standardized acetone-soluble bark fractions: Selecting stem bark extracts standardized to medicarpin, cladrin, and isoformononetin rather than crude total ethanolic bark extracts mitigates unwanted uterotrophic estrogenic stimulation (Pandey et al., 2010; Gupta et al., 2010).
  • Duration caps and washout periods for flower extracts: Limiting continuous flower extract dosing to 8 to 12 weeks with a 45 day washout mitigates reversible testicular weight loss and sperm suppression after 180 days in rats (Parween et al., 2021).
  • Postprandial administration with water: Taking extracts after meals with at least 250 mL of water, as practiced in clinical trials of Palasha Kshara (500 mg three times daily after meals, Kumari & Tukaram, 2022), mitigates gastric mucosal irritation.
  • Scheduled organ and hematological stopping rules: Checking eGFR, albumin, triglycerides, and hemoglobin at baseline, 4 weeks, and 12 weeks, and stopping if eGFR drops >15% or albumin or hemoglobin falls below normal, mitigates subclinical toxicity (Donga et al., 2011).

Therapeutic Protocol

Timing, splitting, cycling, and titration parameters without a citation below reflect common practice.

  • Investigational osteogenic vs. Ayurvedic dosing: Rodent bone studies translate to ~1.6 mg/kg daily (~110 mg daily) of bark isoflavones (Examine; Pandey et al., 2010), whereas Ayurvedic trials give 500 mg Palasha Kshara three times daily (Kumari & Tukaram, 2022).
  • Traditional tissue powder regimens: Ayurvedic practice uses 3 to 6 g daily of flower powder (Palasha Pushpa Churna) or 1 to 3 g daily of gum (Kamarkas), limiting seed powder to brief 1 g doses (Hiremath et al., 2024).
  • Time of day and meal timing: Trials administer Palasha Kshara after meals (Kumari & Tukaram, 2022). Taking extracts with fat-containing morning and midday meals aids isoflavone absorption and avoids evening thermogenic sleep disruption (Jang et al., 2021).
  • Expected half-life: Human half-life is unestablished. In rats, medicarpin peaks in 15 minutes with a 5.3-hour half-life, while cladrin peaks at 3.0 hours with rapid clearance (Taneja et al., 2015; Rashid et al., 2018).
  • Single vs. split dosing: Split dosing two or three times daily (Kumari & Tukaram, 2022) is preferred because medicarpin (17%) and cladrin (7% to 19%) absorption drops at higher doses (Taneja et al., 2015; Rashid et al., 2018).
  • Genetic polymorphisms: Based on rat demethylation and glucuronidation pathways (Wang et al., 2019), individuals with slow UGT1A1 or altered CYP1A2 activity may theoretically experience higher metabolite exposure, favoring conservative starting doses (50% of target) during initial titration.
  • Sex-based differences: Postmenopausal women targeting skeletal maintenance favor non-estrogenic standardized stem bark fractions (Pandey et al., 2010), while reproductive-age men and women avoid chronic flower or seed regimens due to reversible antifertility effects (Parween et al., 2021).
  • Age-related considerations: Older adults with reduced renal filtration and hepatic phase II conjugation start at the lower end of standardized bark extract dosing and avoid crude seed or high-sodium alkaline ash preparations (Donga et al., 2011).
  • Baseline biomarker levels: Baseline DXA (dual-energy X-ray absorptiometry, an imaging scan measuring bone density), CTX-I, fasting glucose, triglycerides, eGFR, and serum albumin establish eligibility and safety thresholds before supplementation (Pandey et al., 2010; Donga et al., 2011).
  • Pre-existing health conditions: Osteopenia and insulin resistance represent primary candidate conditions for standardized bark or flower extracts, whereas chronic kidney disease, hypoalbuminemia, anemia, or hormone-sensitive cancers preclude use (Divya & Mini, 2014; Donga et al., 2011).

Discontinuation & Cycling

  • Treatment duration vs. lifelong use: Published human trials of Butea monosperma span 15 to 60 days (Agarwal et al., 1997; Kumari & Tukaram, 2022). Continuous lifelong use lacks human safety data and is unsupported by clinical evidence.
  • Withdrawal effects and post-cessation persistence: No physiological withdrawal syndrome has been reported. In rats, bone mass gains from stem bark extract and cladrin persisted after treatment withdrawal (Srivastava et al., 2013; Khan et al., 2013).
  • Tapering protocol: Gradual dose tapering is unnecessary upon discontinuation because Butea monosperma constituents do not induce acute rebound phenomena; however, protocols using alcoholic bark extracts for glycemic support typically track fasting glucose after stopping.
  • Cycling for safety and efficacy: Cycling 8–12 weeks on and 4–6 weeks off matches rodent bone regimens (Pandey et al., 2010) and allows testicular recovery, which normalized within 45 days post-withdrawal in rats (Parween et al., 2021).

Sourcing and Quality

  • Plant part verification: Profiles vary by tissue: stem bark supplies osteogenic methoxyisoflavones (Pandey et al., 2010), flowers supply anti-inflammatory chalcones (Rasheed et al., 2010), and seeds contain nephrotoxic palasonin (Donga et al., 2011). Certificates of analysis must confirm zero seed adulteration.
  • Solvent and marker standardization: Unlike inactive aqueous extracts (Ahmed et al., 2012), ethanolic and acetone fractions show efficacy (Pandey et al., 2010). Quality products specify UPLC-MS/MS (ultra-performance liquid chromatography tandem mass spectrometry, a chemical assay) levels of medicarpin (Bajpai et al., 2018).
  • Heavy metal and environmental contaminant screening: Butea monosperma trees growing on industrial fly-ash dumps actively accumulate heavy metals in their tissues (Maiti & Pandey, 2021). Independent third-party testing for lead, arsenic, cadmium, mercury, and microbial contamination is essential before internal use.
  • Botanical authentication and suppliers: Classical Ayurvedic manufacturers (Arya Vaidya Sala Kottakkal, Dhootapapeshwar, Banyan Botanicals) and standardized phytopharmaceutical suppliers (Sami-Sabinsa, Natural Remedies) offer authenticated preparations; genetic barcoding or chromatographic profiling prevents confusion with the Thai species Butea superba.

Practical Considerations

  • Time to effect: Human combination trials showed parasite clearance in 15 days (Agarwal et al., 1997) and urinary stone relief in 8 weeks (Kumari & Tukaram, 2022). Rodent BMD and lipid improvements required 6–12 weeks (Pandey et al., 2010; Divya & Mini, 2014).
  • Common pitfalls: Mistakes include ingesting toxic seed powders instead of bark or flower extracts (Donga et al., 2011), using aqueous teas for glycemic control (Ahmed et al., 2012), and confusing Butea monosperma with Butea superba (a Thai tuber marketed for male sexual function).
  • Regulatory status: Butea monosperma (Palasha) preparations are recognized in the Ayurvedic Pharmacopoeia of India (Kumari & Tukaram, 2022; Hiremath et al., 2024). However, neither standardized extracts nor isolated medicarpin have received clinical drug approval from Western regulators (Kong et al., 2026).
  • Cost and accessibility: Traditional Ayurvedic flower powders, bark decoctions, and Palasha Kshara capsules are inexpensive and widely available through South Asian pharmacies, whereas purified stem bark fractions standardized to medicarpin, cladrin, and cajanin remain scarce outside research settings (Kong et al., 2026).

Interaction with Foundational Habits

  • Sleep: Indirect potentiating and blunting interactions; leaf extracts reduce stress anxiety in rats (Soman et al., 2004), whereas butein-enriched flower fractions stimulate UCP1 thermogenesis and raise core body temperature in mice (Jang et al., 2021). Administering flower extracts in the morning rather than within 6 hours of bedtime prevents thermogenic sleep disruption.
  • Nutrition: Direct potentiating interaction; lipophilic stem bark isoflavones (medicarpin, cladrin, isoformononetin) rely on bile salts for micellar absorption and on intestinal bacteria to convert isoformononetin and daidzein into equol (Raju et al., 2019). Taking extracts with dietary fat and prebiotic fiber enhances bioavailability, whereas separating bark extracts from iron-rich meals avoids tannin chelation.
  • Exercise: Direct potentiating interaction; mechanical loading from resistance training activates osteoblast Wnt/β-catenin signaling, converging with the pathway stimulated by stem bark extracts and medicarpin (Sundar et al., 2024; Dixit et al., 2015). Separating high-dose antioxidant flower extracts by 3–4 hours from workouts avoids theoretically blunting exercise-induced reactive oxygen species signaling.
  • Stress management: Direct potentiating interaction; hydroalcoholic leaf extracts attenuate restraint-stress corticosterone elevation, gastric ulceration, and T-cell immune impairment in rats (Soman et al., 2004; Rizvi et al., 2018). Combining leaf or flower extracts with vagal-tone practices such as slow-paced breathing addresses both neuroendocrine stress reactivity and downstream NF-κB inflammation.

Monitoring Protocol & Defining Success

Before initiating Butea monosperma supplementation, baseline laboratory testing establishes organ safety boundaries and quantifies metabolic and skeletal starting points for longitudinal comparison. Baseline assessment includes serum albumin and total protein, serum creatinine with eGFR, complete blood count, fasting glucose, fasting lipids, and—for individuals targeting skeletal preservation—a baseline DXA scan paired with serum bone turnover markers. Ongoing safety and efficacy monitoring is conducted at 4 and 12 weeks after initiation, and every 6 to 12 months thereafter during cyclic supplementation (with DXA repeated every 12 to 24 months) to detect subclinical organ strain early, guide dose adjustments, or confirm target biomarker improvements over time.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum Albumin and Total Protein Albumin: 3.5–5.0 g/dL; Total Protein: 6.0–8.3 g/dL (standard reference range) Safety check: detects seed-associated hypoalbuminemia and hypoproteinemia (Donga et al., 2011). Draw fasting in the morning as part of a metabolic panel; stop use if albumin falls below 3.5 g/dL.
Serum Creatinine and eGFR Creatinine: 0.6–1.2 mg/dL; eGFR: ≥90 mL/min/1.73 m² (standard reference range) Safety check: screens for palasonin-associated renal tubular or glomerular injury (Donga et al., 2011). Pair with blood urea nitrogen and urinalysis for hematuria (blood in urine) or proteinuria (protein in urine); avoid dehydration prior to draw.
Hemoglobin and Hematocrit Hemoglobin: 13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women); Hematocrit: 36%–50% (standard reference range) Safety check: monitors for seed-associated reductions in red blood cell indices (Donga et al., 2011). Measure as part of a complete blood count at baseline, 4 weeks, and 12 weeks.
Fasting Blood Glucose and Triglycerides Glucose: 70–99 mg/dL; Triglycerides: <150 mg/dL (standard reference range) Safety check and expected-change marker: tracks glycemic and lipid responses or seed-induced hypertriglyceridemia (Divya & Mini, 2014; Donga et al., 2011). Require a 10–12 hour overnight fast; pair with fasting insulin and high-density lipoprotein cholesterol.
Lumbar Spine and Hip BMD (DXA) and Serum CTX-I No established target; track stabilization or increase in BMD and reduction in CTX-I from individual baseline Expected-change marker: evaluates osteogenic and antiresorptive response to stem bark fractions (Pandey et al., 2010). Collect CTX-I fasting between 7:00 and 9:00 AM to minimize circadian variability; pair with serum osteocalcin.
  • Joint comfort and morning stiffness: Track reductions in activity-related joint discomfort when using flower extracts.
  • Gastrointestinal tolerance: Monitor stool frequency, abdominal comfort, and absence of nausea after postprandial dosing.
  • Daytime energy: Note shifts in energy, stress resilience, or warmth.

Emerging Research

  • Absence of registered ClinicalTrials.gov human trials: ClinicalTrials.gov lists no active or completed trials with a registration number for Butea monosperma or its constituents (Kong et al., 2026). A randomized human trial measuring DXA BMD would elevate osteogenic evidence if positive, whereas a null result would confine rodent findings to preclinical status.
  • Siglec15/NFATc1 inhibition and sequential bone maintenance: Preclinical work shows cajanin disrupts Siglec15/NFATc1 (sialic acid-binding immunoglobulin-like lectin 15 and nuclear factor of activated T-cells cytoplasmic 1, proteins driving osteoclast fusion) (Ma et al., 2026) and medicarpin preserves bone mass after parathyroid hormone withdrawal (Sharma et al., 2022).
  • Thermogenic and sirtuin-activating flower fractions: Butein-enriched flower fractions and derivatives induce fat-cell UCP1 and activate SIRT1 and PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a mitochondrial biogenesis regulator) in rodents and human cells (Jang et al., 2021; Chang et al., 2024; Behera et al., 2024).
  • Nanocarrier delivery for neuroprotection: Because flower-derived butrin exhibits poor oral bioavailability and limited blood-brain barrier permeability despite attenuating glutamate excitotoxicity (nerve damage from excess glutamate) and neuroinflammation in preclinical models (Prabhu et al., 2025), emerging research focuses on lipid and polymeric nanocarrier formulations to achieve therapeutic central nervous system concentrations.
  • Endocrine, reproductive, and organ safety boundaries: Male rodent antifertility findings with chronic flower extract (Parween et al., 2021), seed nephrotoxicity (Donga et al., 2011), and computational estrogen-receptor binding predictions (Sindhu & Sripathi, 2026) highlight unresolved endocrine and organ risks that could weaken the longevity case if replicated in human safety studies.

Conclusion

Butea monosperma is a traditional South Asian medicinal tree whose stem bark, flowers, and leaves contain distinct plant compounds investigated for bone preservation, metabolic regulation, and cellular inflammation control. For proactive, risk-aware adults focused on health and longevity, the intervention presents a sharp divide between promising laboratory mechanisms and a nearly absent human clinical evidence base.

Human trials are restricted to small studies where alkaline plant ash was combined with other herbs for acute kidney stones or intestinal parasites—outcomes peripheral to longevity. All standalone longevity-relevant benefits, including hormone-independent bone formation from stem bark compounds, cartilage and skin inflammation suppression from flower compounds, and fat-burning heat production in fat tissue, remain speculative and rest entirely on rodent and cell-culture experiments. Furthermore, much of the foundational bone research originates from a single institutional program that patented standardized stem bark fractions, representing an institutional conflict of interest.

Safety and sourcing depend heavily on plant part selection and extraction method. While purified stem bark and flower extracts were well tolerated in short-term animal studies, crude seed preparations caused kidney bleeding, kidney fat accumulation, low blood protein, elevated blood fats, and red blood cell loss in rodents, and prolonged high-dose flower extracts reversibly impaired male fertility. Oral absorption of the active ring compounds is also low. Consequently, the evidence characterizes Butea monosperma stem bark and flower extracts as early laboratory candidates rather than validated human longevity interventions.

Top - Benefits - Risks - Protocol